DA
PFE icon

Dunvegan Associates’s Pfizer PFE Stock Holding History

Dunvegan Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$83K Hold
2,698
– – 0.1% 73
2015
Q3 		$80K Hold
2,698
– – 0.09% 74
2015
Q2 		$86K Hold
2,698
– – 0.1% 69
2015
Q1 		$89K Hold
2,698
– – 0.08% 87
2014
Q4 		$80K Hold
2,698
– – 0.07% 88
2014
Q3 		$76K Hold
2,698
– – 0.07% 81
2014
Q2 		$76K Sell
2,698
-1,017
-27% -$29K 0.06% 85
2014
Q1 		$113K Buy
+3,715
New +$111K 0.1% 73

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dunvegan Associates's PFE Position: Q4 2015 in Review

Dunvegan Associates held its Pfizer (PFE) position steady in Q4 2015 at 2,698 shares worth $83K. The position accounts for 0.1% of the portfolio, ranked #73.

Dunvegan Associates first reported a position in PFE in Q1 2014 and has held it in 8 quarters since. The position peaked at $113K in Q1 2014. 1,970 funds tracked by Wall St. Rank hold PFE as of Q4 2015.

  • Dunvegan Associates held 2,698 shares of Pfizer worth $83K as of Q4 2015.
  • Dunvegan Associates left its Pfizer share count unchanged in Q4 2015.
  • Pfizer made up 0.1% of Dunvegan Associates's portfolio in Q4 2015, its #73 holding.
  • Dunvegan Associates first reported a position in Pfizer in Q1 2014 and has held it in 8 quarters since.
  • Dunvegan Associates's Pfizer position peaked at $113K in Q1 2014.
  • 1,970 funds tracked by Wall St. Rank held Pfizer as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.